Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing, because the oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. But what can you do? The world keeps spinning, no matter what. So on that note, please join us for a needed cup or three of stimulation — we fancy butter pecan today, if suggestions are needed — and enjoy the menu of tidbits assembled for you. Hope you have a smashing day and, as always, please do keep in touch …
An unnamed Novartis (NVS) executive sold $946,000 worth of shares less than three weeks before the Food and Drug Administration announced data from tests of its Zolgensma gene therapy were manipulated, Reuters writes. The stock sale by an executive member of the board or executive committee was disclosed in a July 19 Swiss stock exchange filing. Novartis says “the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”
About the Author Reprints
